Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Sardi SP"" wg kryterium: Autor

  Lista filtrów
Wyrównaj
    Wyświetlanie 1-5 z 5
    Tytuł:
    Glucocerebrosidase Deficiency in Drosophila Results in α-Synuclein-Independent Protein Aggregation and Neurodegeneration.
    Autorzy:
    Davis MY; Department of Neurology, University of Washington, Seattle, Washington, United States of America.; Department of Genome Sciences, University of Washington, Seattle, Washington, United States of America.
    Trinh K; Department of Genome Sciences, University of Washington, Seattle, Washington, United States of America.
    Thomas RE; Department of Genome Sciences, University of Washington, Seattle, Washington, United States of America.
    Yu S; Department of Genome Sciences, University of Washington, Seattle, Washington, United States of America.
    Germanos AA; Department of Genome Sciences, University of Washington, Seattle, Washington, United States of America.
    Whitley BN; Department of Biochemistry, University of Washington, Seattle, Washington, United States of America.
    Sardi SP; Neuroscience, Rare Diseases Research Unit, Sanofi Genzyme, Framingham, Massachusetts, United States of America.
    Montine TJ; Department of Pathology, University of Washington, Seattle, Washington, United States of America.
    Pallanck LJ; Department of Genome Sciences, University of Washington, Seattle, Washington, United States of America.
    Pokaż więcej
    Źródło:
    PLoS genetics [PLoS Genet] 2016 Mar 28; Vol. 12 (3), pp. e1005944. Date of Electronic Publication: 2016 Mar 28 (Print Publication: 2016).
    Typ publikacji:
    Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Gaucher Disease/*genetics
    Glucosylceramidase/*genetics
    Nerve Degeneration/*genetics
    Parkinson Disease/*genetics
    alpha-Synuclein/*genetics
    Animals ; Dopaminergic Neurons/metabolism ; Dopaminergic Neurons/pathology ; Drosophila melanogaster ; Gaucher Disease/metabolism ; Gaucher Disease/pathology ; Glucosylceramidase/metabolism ; Humans ; Lysosomes/genetics ; Lysosomes/pathology ; Nerve Degeneration/pathology ; Parkinson Disease/metabolism ; Parkinson Disease/pathology ; Phenotype ; Protein Aggregation, Pathological
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Safety, Pharmacokinetics, and Pharmacodynamics of Oral Venglustat in Patients with Parkinson's Disease and a GBA Mutation: Results from Part 1 of the Randomized, Double-Blinded, Placebo-Controlled MOVES-PD Trial.
    Autorzy:
    Peterschmitt MJ; Sanofi, Cambridge, MA, USA.
    Saiki H; Kitano Hospital, The Tazuke Kofukai Medical Research Institute, Osaka, Japan.
    Hatano T; Juntendo University, Tokyo, Japan.
    Gasser T; Neurologische Universitätsklinik, Tübingen, Germany; German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany.
    Isaacson SH; Parkinson's Disease and Movement Disorders Center, Boca Raton, FL, USA.
    Gaemers SJM; Sanofi Genzyme, Amsterdam, Netherlands.
    Minini P; Sanofi, Chilly-Mazarin, France.
    Saubadu S; Sanofi, Chilly-Mazarin, France.
    Sharma J; Sanofi, Bridgewater, NJ, USA.
    Walbillic S; Sanofi, Chilly-Mazarin, France.
    Alcalay RN; Department of Neurology and the Taub Institute, Columbia University Medical Center, New York, NY, USA.
    Cutter G; University of Alabama at Birmingham, School of Public Health, Birmingham, AL, USA.
    Hattori N; Juntendo University, Tokyo, Japan.
    Höglinger GU; German Center for Neurodegenerative Diseases (DZNE), Munich, and Department of Neurology, Klinikum Rechts der Isar, Technical University Munich, Munich, Germany.; Department of Neurology, Hannover Medical School, Hannover, Germany.
    Marek K; Institute for Neurodegenerative Disorders, New Haven, CT, USA.
    Schapira AHV; Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, University College London, London, UK.
    Scherzer CR; Harvard Medical School and Brigham & Women's Hospital, Boston, MA, USA.
    Simuni T; Northwestern University, Chicago, IL, USA.
    Giladi N; Neurological Institute, Tel Aviv Medical Center, Sackler School of Medicine, Sagol School of Neuroscience, Tel Aviv University, Tel Aviv, Israel.
    Sardi SP; Sanofi, Cambridge, MA, USA.
    Fischer TZ; Sanofi, Cambridge, MA, USA.
    Pokaż więcej
    Corporate Authors:
    MOVES-PD Investigators
    Źródło:
    Journal of Parkinson's disease [J Parkinsons Dis] 2022; Vol. 12 (2), pp. 557-570.
    Typ publikacji:
    Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Glucosylceramidase*/genetics
    Parkinson Disease*/drug therapy
    Parkinson Disease*/genetics
    Adolescent ; Adult ; Aged ; Aged, 80 and over ; Enzyme Inhibitors/adverse effects ; Glucosylceramides ; Humans ; Middle Aged ; Mutation ; Young Adult
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Accelerating diagnosis of Parkinson's disease through risk prediction.
    Autorzy:
    Yuan W; Department of Biomedical Informatics, Harvard Medical School, 10 Shattuck Street, Suite 514, Boston, MA, 02115, USA.
    Beaulieu-Jones B; Department of Biomedical Informatics, Harvard Medical School, 10 Shattuck Street, Suite 514, Boston, MA, 02115, USA.
    Krolewski R; Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA, 02138, USA.; Department of Neurology, Brigham and Women's Hospital, Boston, MA, 02115, USA.
    Palmer N; Department of Biomedical Informatics, Harvard Medical School, 10 Shattuck Street, Suite 514, Boston, MA, 02115, USA.
    Veyrat-Follet C; Sanofi, 1 Av. Pierre Brossolette, 91380, Chilly-Mazarin, France.
    Frau F; Sanofi-Aventis Deutschland GmbH, Industriepark Höchst, 65926, Frankfurt am Main, Germany.
    Cohen C; Sanofi, 1 Av. Pierre Brossolette, 91380, Chilly-Mazarin, France.
    Bozzi S; Sanofi, 1 Av. Pierre Brossolette, 91380, Chilly-Mazarin, France.
    Cogswell M; Sanofi, 50 Binney St, Cambridge, MA, 02142, USA.
    Kumar D; Sanofi, 50 Binney St, Cambridge, MA, 02142, USA.
    Coulouvrat C; Sanofi, 1 Av. Pierre Brossolette, 91380, Chilly-Mazarin, France.
    Leroy B; Sanofi, 1 Av. Pierre Brossolette, 91380, Chilly-Mazarin, France.
    Fischer TZ; Sanofi, 50 Binney St, Cambridge, MA, 02142, USA.
    Sardi SP; Sanofi, 50 Binney St, Cambridge, MA, 02142, USA.
    Chandross KJ; Sanofi R&D, 55 Corporate Drive, Bridgewater, NJ, 08807, USA.
    Rubin LL; Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA, 02138, USA.
    Wills AM; Neurological Clinical Research Institute (NCRI), Massachusetts General Hospital (MGH), Boston, MA, 02114, USA.
    Kohane I; Department of Biomedical Informatics, Harvard Medical School, 10 Shattuck Street, Suite 514, Boston, MA, 02115, USA.
    Lipnick SL; Department of Biomedical Informatics, Harvard Medical School, 10 Shattuck Street, Suite 514, Boston, MA, 02115, USA. .; Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA, 02138, USA. .; Center for Assessment Technology and Continuous Health, Massachusetts General Hospital, Boston, MA, 02114, USA. .
    Pokaż więcej
    Źródło:
    BMC neurology [BMC Neurol] 2021 May 18; Vol. 21 (1), pp. 201. Date of Electronic Publication: 2021 May 18.
    Typ publikacji:
    Journal Article
    MeSH Terms:
    Parkinson Disease/*diagnosis
    Gait/physiology ; Gait Analysis ; Humans ; Machine Learning ; Retrospective Studies ; Risk Assessment ; Tremor
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Longitudinal Measurements of Glucocerebrosidase activity in Parkinson's patients.
    Autorzy:
    Alcalay RN; Department of Neurology, Columbia University Irving Medical Center New York, New York, USA.
    Wolf P; Translational Sciences, Sanofi, Framingham, Massachusetts, USA.
    Chiang MSR; Rare and Neurological Diseases Therapeutic Area, Sanofi, Framingham, Massachusetts, USA.
    Helesicova K; Translational Sciences, Sanofi, Framingham, Massachusetts, USA.
    Zhang XK; Translational Sciences, Sanofi, Framingham, Massachusetts, USA.
    Merchant K; Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
    Hutten SJ; The Michael J. Fox Foundation for Parkinson's Research, New York, New York, USA.
    Scherzer C; Advanced Center for Parkinson's Disease Research of Brigham & Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.; Precision Neurology Program, Harvard Medical School, Brigham & Women's Hospital, Boston, Massachusetts, USA.; Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA.
    Caspell-Garcia C; Department of Biostatistics, College of Public Health, University of Iowa, Iowa City, Iowa, USA.
    Blauwendraat C; Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, Maryland, USA.
    Foroud T; Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA.
    Nudelman K; Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA.
    Gan-Or Z; Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada.; Montreal Neurological Institute and Hospital, McGill University, Montreal, Quebec, Canada.; Department of Human Genetics, McGill University, Montreal, Quebec, Canada.
    Simuni T; Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
    Chahine LM; Department of Neurology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
    Levy O; Department of Neurology, Columbia University Irving Medical Center New York, New York, USA.
    Zheng D; Department of Biostatistics, Mailman School of Public Health, Columbia University Irving Medical Center New York, New York, USA.
    Li G; Department of Biostatistics, Mailman School of Public Health, Columbia University Irving Medical Center New York, New York, USA.
    Sardi SP; Rare and Neurological Diseases Therapeutic Area, Sanofi, Framingham, Massachusetts, USA.
    Pokaż więcej
    Corporate Authors:
    Parkinson’s Progression Markers Initiative
    Źródło:
    Annals of clinical and translational neurology [Ann Clin Transl Neurol] 2020 Oct; Vol. 7 (10), pp. 1816-1830. Date of Electronic Publication: 2020 Sep 05.
    Typ publikacji:
    Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Dementia/*physiopathology
    Glucosylceramidase/*metabolism
    Parkinson Disease/*metabolism
    Parkinson Disease/*pathology
    Adult ; Dementia/complications ; Dementia/pathology ; Disease Progression ; Female ; Genotype ; Glucosylceramidase/genetics ; Heterozygote ; Humans ; Male ; Mental Status and Dementia Tests ; Middle Aged ; Mutation/genetics ; Parkinson Disease/complications ; Phenotype
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Cerebrospinal fluid proteomics implicates the granin family in Parkinson's disease.
    Autorzy:
    Rotunno MS; Rare and Neurologic Diseases Therapeutic Area, Sanofi, Inc., Framingham, MA, 01701, USA.; Biomarkers and Bioanalytics, Translational Sciences, Sanofi, Inc., Framingham, MA, 01701, USA.
    Lane M; Biomarkers and Bioanalytics, Translational Sciences, Sanofi, Inc., Framingham, MA, 01701, USA.
    Zhang W; Translational Medicine, Sanofi, Inc., Framingham, MA, 01701, USA.
    Wolf P; Biomarkers and Bioanalytics, Translational Sciences, Sanofi, Inc., Framingham, MA, 01701, USA.; Editas Medicine, Cambridge, MA, 02141, USA.
    Oliva P; Biomarkers and Bioanalytics, Translational Sciences, Sanofi, Inc., Framingham, MA, 01701, USA.; ARCHIMED Life Sciences GmbH, Leberstraße 20/2, 1110, Vienna, Austria.
    Viel C; Rare and Neurologic Diseases Therapeutic Area, Sanofi, Inc., Framingham, MA, 01701, USA.
    Wills AM; Department of Neurology, Massachusetts General Hospital, Boston, MA, 02114, USA.
    Alcalay RN; Department of Neurology, Columbia University, New York, NY, 10032-3784, USA.
    Scherzer CR; Precision Neurology Program, Harvard Medical School, Brigham & Women's Hospital, Boston, MA, 02115, USA.; Department of Neurology, Massachusetts General Hospital, Boston, MA, 02114, USA.; APDA Center for Advance Parkinson Research, Harvard Medical School, Brigham & Women's Hospital, Boston, MA, 02115, USA.
    Shihabuddin LS; Rare and Neurologic Diseases Therapeutic Area, Sanofi, Inc., Framingham, MA, 01701, USA.
    Zhang K; Biomarkers and Bioanalytics, Translational Sciences, Sanofi, Inc., Framingham, MA, 01701, USA.; Editas Medicine, Cambridge, MA, 02141, USA.
    Sardi SP; Rare and Neurologic Diseases Therapeutic Area, Sanofi, Inc., Framingham, MA, 01701, USA. pablo.sardi@sanofi.com.
    Pokaż więcej
    Źródło:
    Scientific reports [Sci Rep] 2020 Feb 12; Vol. 10 (1), pp. 2479. Date of Electronic Publication: 2020 Feb 12.
    Typ publikacji:
    Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Chromogranins/*cerebrospinal fluid
    Parkinson Disease/*cerebrospinal fluid
    Aged ; Biomarkers/cerebrospinal fluid ; Female ; Humans ; Male ; Middle Aged ; Proteomics ; Tandem Mass Spectrometry
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
      Wyświetlanie 1-5 z 5

      Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies